Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Athersys Inc.
  • Celldex Therapeutics Inc.
  • Cempra Inc.
  • Cyberonics Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Corp.
  • Navidea Biopharmaceuticals Inc.
  • NeoStem Inc.
  • Omeros Corp.
  • Prosensa Holding N.V.
  • Sarepta Therapeutics Inc.
  • Tetraphase Pharmaceuticals Inc.

Steve Brozak

WBB Securities

Image: Steve Brozak

Stephen G. Brozak is a top-ranked analyst in biotechnology, pharmaceuticals and medical devices according to the Starmine ranking system and The Wall Street Journal. He has worked in the securities industry for more than 25 years, where he held positions in sales, management, investment banking, and research analysis. He is now the Managing Partner and President of WBB Securities, an independent broker/dealer and full-service investment bank. Brozak holds a bachelor’s degree and a master’s degree in business administration from Columbia University. He is a retired lieutenant colonel in the United States Marine Corps and currently is a member of the Secretary of Navy's Retiree Council, advising on healthcare issues.




Recent Interviews

Do Away with the Pill-A-Day Biotech Model: Steve Brozak (2/6/14) The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new paradigm, in which budgets are restrained and companies generate curative therapies for unmet needs. In this interview with The Life Sciences Report, Brozak takes aim at a broken system and lists ten problem-solving companies that can adapt to the changes he believes must take place for healthcare to be profitable and productive. A bonus: These companies can also add vigor to investment portfolios.

Companies that Can Mend the Biotech Market: Stephen Brozak (4/11/13) Markets are not efficient—at least not in the short term. WBB Securities President Stephen Brozak admits to frustration when he sees small-cap companies with valuations that are disengaged from market realities. But Brozak's experience as a biotech investor, banker and analyst has taught him to be patient with these disconnection syndromes, and he now delights in prospects offered by select bargain-basement opportunities. In this interview with The Life Sciences Report, Brozak touches on 10 names that have been flying far below the radars of most investors.

Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured (1/24/13) Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider.

Recent Quotes

"I think it would be easy for OMER to single-handedly take the market." (2/6/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"NBS' initial trial data has been positive beyond expectations." (2/6/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"We believe ATHX is still undervalued." (2/6/14) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >

"There is exciting potential for CYTX's therapy." (2/6/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Steve Brozak More >

"We rate ATHX a Strong Buy for its fantastic progress in Japan and its continued positive work in the U.S." (1/9/14) Athersys Inc. - Steve Brozak, WBB Securities More >

"NBS has crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial; safety looks good and enrollment should be completed this year." (4/11/13) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >



Due to permission requirements, not all quotes are shown.